742 related articles for article (PubMed ID: 25998713)
1. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.
Rao RC; Dou Y
Nat Rev Cancer; 2015 Jun; 15(6):334-46. PubMed ID: 25998713
[TBL] [Abstract][Full Text] [Related]
2. Biochemical perspectives on targeting KMT2 methyltransferases in cancer.
Zhai X; Brownell JE
Trends Pharmacol Sci; 2021 Aug; 42(8):688-699. PubMed ID: 34074527
[TBL] [Abstract][Full Text] [Related]
3. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
Fagan RJ; Dingwall AK
Cancer Lett; 2019 Aug; 458():56-65. PubMed ID: 31128216
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Activity of Histone-Lysine N-Methyltransferase 2 (KMT2) Complexes in Oncogenesis.
Poreba E; Lesniewicz K; Durzynska J
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302406
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional regulation by the KMT2 histone H3K4 methyltransferases.
Park K; Kim JA; Kim J
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194545. PubMed ID: 32194213
[TBL] [Abstract][Full Text] [Related]
6. Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers.
Zhang P; Huang Y
J Hematol Oncol; 2021 Mar; 14(1):39. PubMed ID: 33653367
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for activity regulation of MLL family methyltransferases.
Li Y; Han J; Zhang Y; Cao F; Liu Z; Li S; Wu J; Hu C; Wang Y; Shuai J; Chen J; Cao L; Li D; Shi P; Tian C; Zhang J; Dou Y; Li G; Chen Y; Lei M
Nature; 2016 Feb; 530(7591):447-52. PubMed ID: 26886794
[TBL] [Abstract][Full Text] [Related]
8. The cancer COMPASS: navigating the functions of MLL complexes in cancer.
Ford DJ; Dingwall AK
Cancer Genet; 2015 May; 208(5):178-91. PubMed ID: 25794446
[TBL] [Abstract][Full Text] [Related]
9. KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions.
Van HT; Xie G; Dong P; Liu Z; Ge K
J Mol Biol; 2024 Apr; 436(7):168453. PubMed ID: 38266981
[TBL] [Abstract][Full Text] [Related]
10. Why are so many MLL lysine methyltransferases required for normal mammalian development?
Crump NT; Milne TA
Cell Mol Life Sci; 2019 Aug; 76(15):2885-2898. PubMed ID: 31098676
[TBL] [Abstract][Full Text] [Related]
11. Structural insights on the KMT2-NCP interaction.
Yang Z; Zepeda R; Dou Y
Biochem Soc Trans; 2023 Feb; 51(1):427-434. PubMed ID: 36695549
[TBL] [Abstract][Full Text] [Related]
12. Evolving Catalytic Properties of the MLL Family SET Domain.
Zhang Y; Mittal A; Reid J; Reich S; Gamblin SJ; Wilson JR
Structure; 2015 Oct; 23(10):1921-1933. PubMed ID: 26320581
[TBL] [Abstract][Full Text] [Related]
13. Histone-lysine N-methyltransferase 2 (KMT2) complexes - a new perspective.
Poreba E; Lesniewicz K; Durzynska J
Mutat Res Rev Mutat Res; 2022; 790():108443. PubMed ID: 36154872
[TBL] [Abstract][Full Text] [Related]
14. Insights on the regulation of the MLL/SET1 family histone methyltransferases.
Sha L; Ayoub A; Cho US; Dou Y
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194561. PubMed ID: 32304759
[TBL] [Abstract][Full Text] [Related]
15. Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia.
Cermáková K; Tesina P; Demeulemeester J; El Ashkar S; Méreau H; Schwaller J; Rezáčová P; Veverka V; De Rijck J
Cancer Res; 2014 Sep; 74(18):5139-51. PubMed ID: 25082813
[TBL] [Abstract][Full Text] [Related]
16. Targeting human SET1/MLL family of proteins.
Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T
Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335
[TBL] [Abstract][Full Text] [Related]
17. The role of KMT2 gene in human tumors.
Zhang ZL; Yu PF; Ling ZQ
Histol Histopathol; 2022 Apr; 37(4):323-334. PubMed ID: 35233758
[TBL] [Abstract][Full Text] [Related]
18. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
19. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L.
Stein EM; Tallman MS
Curr Opin Hematol; 2015 Mar; 22(2):92-6. PubMed ID: 25635757
[TBL] [Abstract][Full Text] [Related]
20. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
